



*You're invited to the 25<sup>th</sup> INTERNATIONAL*  
**Thyroid Cancer Survivors' Virtual Conference**  
**September 16-18, 2022**


Sponsored by ThyCa: Thyroid Cancer Survivors' Association, Inc.<sup>SM</sup> • [www.thyca.org](http://www.thyca.org)

**Confirmed Speakers** as of September 15, 2022  
Meet and learn from these experts!

**Sarimar N. Agosto Salgado, MD**, is an oncologic endocrinologist at Moffitt Cancer Center in Tampa, Florida. Dr. Agosto Salgado's clinical interest centers on the management of thyroid nodules and all stages and types of thyroid cancer, including administration of systemic therapies for aggressive tumors. She is also interested in the management of hereditary endocrine neoplasia disorders, pituitary tumors, adrenal tumors, adrenocortical carcinoma and pheochromocytoma-paraganglioma tumors. Her research interest focuses on intermediate-high risk thyroid cancers in terms of management, surveillance protocols, targeted therapies and potential redifferentiation of tumors resistant to radioactive iodine.



**Shahzad Ahmad, MD**, is an endocrinologist at The Thyroid Clinic in Salt Lake City, Utah. Dr. Ahmad has performed more radiofrequency ablation (RFA) procedures than any endocrinologist in the US. He performed the first successful RFA procedure of a parathyroid tumor and the first RFA of a medullary thyroid cancer recurrence in North America. Dr. Ahmad also has performed the first RFA procedure on a toxic thyroid nodule (hyperfunctioning) in the US. Dr. Ahmad completed his residency in Internal Medicine at Mount Sinai School of Medicine in Englewood, New Jersey and then went on to an Endocrine fellowship at UCLA-Harbour. He was also an Assistant Professor at the University of San Francisco School of Medicine. His primary focus is the diagnosis, and medical treatment of thyroid dysfunction, nodules, and cancer. Dr. Ahmad is ECNU certified, a professional certification awarded to Endocrinologists who have expertise in thyroid ultrasounds, and procedures. Dr. Ahmad has been involved in trying to bring RFA to the USA for over 4 years and has extensively practiced this technique on tissue models. He has now successfully ablated over 150 nodules/Goiters without complications



**Jules Aljammal, MD, ECNU**, is an endocrinologist at The Thyroid Clinic in Salt Lake City, Utah. Dr. Aljammal completed his fellowship in endocrinology at the University Of Pittsburgh Medical Center in 2014. Thereafter, he started his own medical practice in Salt Lake City, Utah, which is completely focused on the management of thyroid and parathyroid disorders. He has extensive experience in performing RFA, which he first brought to Salt Lake City in 2018. Since that time, he has performed more than 300 cases and has published his work in "Journal of the Endocrine Society". His most recent paper on thermal ablation is the first to be published in the United States by an endocrinologist. Lastly, to promote interest and advance the field of interventional endocrinology, he created the North American Society of Interventional Endocrinologist and currently serves as its first President.



**Douglas W. Ball, MD**, is an endocrinologist at Johns Hopkins Medicine in Baltimore, Maryland. Dr. Ball is an associate professor of medicine specializing in Thyroid Cancer, Medullary Thyroid Cancer, and Multiple Endocrine Neoplasia. His laboratory studies mechanisms underlying the neuroendocrine phenotype seen in some human cancers. Dr. Ball is active in developing new therapies for medullary thyroid cancer, and works in this translational research program in collaboration with other researchers and clinicians. Dr. Ball graduated from George Washington University Medical School and completed further training in Internal Medicine and in Endocrinology and Metabolism at the University of Pittsburgh and Johns Hopkins University. He is the author of numerous peer-reviewed medical journal articles and has been a speaker at previous ThyCa educational events. He is a ThyCa medical advisor.



**Zubair W. Baloch, MD, PhD**, is professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania. He earned his medical degree from Liaquat Medical College in Jamshoro, Pakistan and his PhD from Hahnemann University in Philadelphia. Dr. Baloch's research expertise is in molecular and immunopathology of thyroid neoplasia and his clinical expertise is in endocrine pathology (cytology and histopathology).



**Valerie Bastani, BSN, RN, OCN**, is an oncology nurse educator on the Precision Medicine Team at Bayer HealthCare Pharmaceuticals. She has been an active member of the Oncology Nursing Society (ONS) since 1996 and has held several board positions within her local chapter. Valerie earned the Oncology Nursing accreditation in 2004 and maintained certification throughout her nursing career. She received her Bachelor of Science in Nursing from Florida State University. She is responsible for educating clinical staff about adverse event management and oncology disease states. Valerie gained most of her clinical experience as a Clinical Nurse Manager, spending over 15 years at 2 large oncology practices in Orlando, Florida. She was also on the Florida Hospital IV Specialty Team as a Venous Access Specialist. Valerie is passionate about education and patient advocacy.




**Shari Bates, BSN, RN, OCN, CCM**, is an oncology nurse educator on the precision medicine team at Bayer HealthCare Pharmaceuticals based out of the state of Washington. Prior to transitioning to a nurse educator role in 2017, she held the position of Oncology Nurse Navigator at UW Medicine Valley Medical Center in Renton, Washington. Her clinical background encompasses experience in neuro-oncology, community practice, and specialty case management. She holds certifications in Oncology Nursing, Case Management, and Care Coordination and Transition Management.



**Andrew J. Bauer, MD, FAAP**, is a pediatric endocrinologist and the director of the Thyroid Center at The Children's Hospital of Philadelphia in Philadelphia, Pennsylvania. Dr. Bauer retired from the United States Army after 29 years of service, to include two combat tours in Iraq. His clinical and research interests are focused on the study of pediatric thyroid disorders, including hyperthyroidism, hypothyroidism, thyroid nodular disease, thyroid cancer, and familial thyroid tumor syndromes. Dr. Bauer serves as co-chair of the American Thyroid Association's (ATA) Pediatric Thyroid Cancer Guidelines and as a member of the ATA's board of directors. In 2018, Dr. Bauer served on the World Health Organization, International Agency for Research on Cancer expert group that published guidelines on thyroid screening after nuclear disasters. He has spoken at many ThyCa events. Dr. Bauer is a ThyCa medical advisor.



**Erik Blomain, MD, PhD**, is a radiation oncologist at Stanford University in California. Dr. Blomain earned his undergraduate degrees at Cornell University majoring in both Biology and Classic Civilizations. He completed the MD/PhD Program and completed his medical internship at Thomas Jefferson University in Philadelphia. His focus is on translational cancer research as well as patient-centered care, advocacy, and survivorship for cancer patients.



**Monica Fawzy Bryant, Esq.** is a cancer rights attorney at Triage Cancer Center in Chicago, Illinois. Ms. Bryant is the chief operating officer for Triage Cancer, a national, nonprofit organization that provides education and resources on cancer survivorship issues. Throughout her career, Ms. Bryant has provided hundreds of educational seminars, written articles, and blogs, and appeared on community television and radio shows discussing healthcare-related legal issues. Ms. Bryant is an adjunct law professor at John Marshall School of Law in Chicago, teaching a class on Cancer Rights. Ms. Bryant currently serves on the executive committee of the American Bar Association's Breast Cancer Task Force. She focuses on disability insurance; employment rights; estate planning and medical decision making; financial health, legislative advocacy; health insurance options; health insurance navigation; and health care reform.



**Naifa L. Busaidy, MD**, is an endocrinologist and associate professor in the Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Busaidy, the director of the Thyroid Nodule Clinic, specializes in thyroid cancer and has authored numerous peer-reviewed research articles and book chapters. Dr. Busaidy is a recipient of a ThyCa thyroid cancer research grant and has spoken at many ThyCa conferences. She is a ThyCa medical advisor. Dr. Busaidy is a 2011 ThyCa research grant recipient.



**Maria E. Cabanillas, MD**, is an oncologic endocrinologist, professor, and the faculty director at the University of Texas MD Anderson Cancer Center in Houston, Texas. She is the faculty director of clinical research in the Department of Endocrine Neoplasia at MD Anderson. As a clinician and clinical researcher, Dr. Cabanillas treats both early and advanced thyroid cancers, including medullary, differentiated, and anaplastic. Her research focus is in advanced and aggressive thyroid cancer and molecular targeted therapies and immunotherapy. She is a principal investigator on several clinical trials for treating advanced disease and has been a member of and currently serves on the board of directors of the International Thyroid Oncology Group (ITOG). She is a ThyCa medical advisor.



**Alaina Carr, PhD**, is a clinical psychologist at Georgetown University in Washington, DC. Dr. Carr received her bachelor's degree in Psychology from the University of Colorado Boulder and her doctoral in Clinical Health Psychology from the University of Colorado Denver. She also completed the Meaning-Centered Psychotherapy Program for Cancer Care Providers at Memorial Sloan Kettering. Dr. Carr has specialized experience working with cancer patients and their family members (or caregivers) across the cancer care continuum (e.g., diagnosis, treatment, survivorship, and end-of-life). She works with clients to help them better cope with health-related stress.



**Ruth Casey, MD**, is a consultant endocrinologist at Cambridge University Hospital NHS Foundation Trust and senior research associate in the department of medical genetics at Cambridge University in Cambridge, United Kingdom. Dr Casey leads neuroendocrine tumour (NET) and endocrine cancer services in Cambridge and is the endocrine lead for the endocrine genetics service, encompassing both clinical practice and independently funded research in GIST, pheochromocytoma and paraganglioma. She has a specialist research interest in SDH deficient tumours and the molecular mechanisms underpinning endocrine cancers. Dr Casey is also the clinical convenor for the Society for Endocrinology Endocrine Cancer Network and a member of the International SDH consortium and an advisor for the patient group AMEND (Association for Multiple Endocrine Neoplasia Disorders).



**Francesco S. Celi, MD, MHSc**, is the William G. Blackard Professor of Medicine and chair of the Division of Endocrinology Diabetes and Metabolism at Virginia Commonwealth University (VCU) in Richmond, Virginia. Prior to joining the faculty of VCU, Dr. Celi worked for ten years as clinical investigator at the National Institutes of Health, National Institute of Diabetes Digestive and Kidney Diseases in Bethesda, Maryland. He is a graduate of the University of Rome "La Sapienza", and a diplomate of the American Board of Internal Medicine, with subspecialty in endocrinology, diabetes, and metabolism Dr. Celi conducts both clinical and translational research and his scientific interest is focused on the physiology and pathophysiology of thyroid hormone action as it relates to energy metabolism. Dr. Celi's clinical interests are thyroid disease, with a specific focus on thyroid ultrasound, fine needle aspiration biopsy, and multidisciplinary management of thyroid cancer.



**Mark S. Chambers, DMD, MS**, is chief of the section of Oral Oncology and Maxillofacial Prosthodontics in the Department of Head and Neck Surgery at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is the vice chair of Research Compliance and Regulatory Affairs. His clinical research efforts include studying the effects of stimulants, antibiotics, and enhancing the body's immune system to manage dry mouth and injuries to the mouth caused by radiation and/or chemotherapy. Dr. Chambers earned his DMD and an MS in Biological Sciences at the University of Louisville in Kentucky. Dr. Chambers is a ThyCa medical advisor.






**Naveen Chaubal** is a film producer. Naveen is a fellow of Film Independent's Project: Involve and Fast Track programs. His short film "Pinball" screened at the DGA and premiered online on NoBudget.com and won Audience Choice. He co-produced Tomorrow We Disappear, a feature documentary about the last days of a New Delhi artist's colony which screened at Hot Docs. Naveen has worked for AJ+, Vice News, and produced music videos for James Blake and Frank Ocean. He earned his BA from USC School of Cinematic Arts



**Jennifer Choe, MD, PhD**, is a medical oncologist at the Vanderbilt-Ingram Cancer Center who specializes in head and neck cancers, including thyroid cancers and cutaneous squamous cell carcinomas. She received her combined M.D. and Ph.D. from the University of Texas at Houston Health Sciences Center and MD Anderson Cancer Center followed by Internal Medicine residency at Baylor College of Medicine and Hematology-Oncology fellowship training at Duke University. She was faculty at Duke for 5 years leading their Head and Neck Medical Oncology and Clinical Research Program in addition to Associate Director for the Duke Center for Cancer Immunotherapy until joining Vanderbilt-Ingram Cancer Center. Her primary interest is in clinical trial development of investigational drugs with a research focus in novel immunotherapeutics. She is an active clinical investigator in the Head and Neck and Phase I clinical trial teams.



**Roger B. Cohen, MD**, is a professor of medicine at the University of Pennsylvania. He is a graduate of Harvard Medical School and completed internal medicine and hematology training at Mount Sinai Hospital (NY) followed by research fellowships at the Memorial Sloan-Kettering Cancer Center and National Institutes of Health and a medical oncology fellowship at the National Cancer Institute. He was a medical officer at the FDA Center for Biologics from 1989-1994 and was Deputy Director, Division of Monoclonal Antibodies. Prior to his arrival at Penn, Dr. Cohen was Director of the Cancer Center Clinical Trials Office at the University of Virginia Cancer Center in Charlottesville and then Director of the Phase 1 Program at the Fox Chase Cancer Center. He is an active investigator on several first-in-humans clinical trials with research interests that focus on evaluation of novel therapies, including monoclonal antibodies, immune therapies, and small molecule cell-signaling pathway inhibitors. He primarily sees patients with lung and head and neck cancer.



**Louise Davies, MD, MS, FACS**, is an otolaryngologist and associate professor of surgery, Dartmouth Geisel School of Medicine, Hanover, New Hampshire. She also serves as Chief of Otolaryngology—Head & Neck Surgery. She spent the 2017-2018 academic year as a Fulbright Global Scholar grantee, traveling to Japan and England to do research on thyroid cancer and gain expertise in surgical clinical trial design and implementation. She is best known for her work to define and mitigate the problem of overdiagnosis in thyroid cancer. She is a subject matter expert reviewer for the U.S. Preventive Services Task Force on thyroid cancer screening, on a task force for the International Agency for Research on Cancer, Lyon, France to make recommendations about thyroid monitoring after nuclear accidents, and as an advisor to the state of North Carolina on thyroid cancer cluster evaluation.



**Kimberly Davis, PhD**, is a research associate professor in the Departments of Psychiatry and Oncology and the Director of Psychosocial Oncology in the Lombardi Comprehensive Cancer Center (LCCC) at the Medstar Georgetown University Medical Center in Washington, DC. Dr. Davis received her doctoral degree in clinical health psychology from Washington University in St. Louis, MO. She completed her residency at RUSH St. Luke's Presbyterian Medical Center in Chicago, IL. At the Lombardi Comprehensive Cancer Center, Dr. Davis provides psychosocial services for patients, families, and survivors throughout the continuum of cancer care.



**Kaniksha Desai, MD, ECNU**, is an endocrinologist and clinical assistant professor of endocrinology at Stanford University in Palo Alto, California. She completed her endocrinology fellowship at the Mayo Clinic in Jacksonville, Florida, with an emphasis on the management of patients with thyroid cancer. Dr. Desai's clinical practice, located in the Endocrinology Clinic Hoover Pavilion, Palo Alto, California, focuses on the management of patients with thyroid diseases, including thyroid nodules and thyroid cancers, and the management of patients with pituitary disorders. She also maintains board certification in neck ultrasonography and internal medicine.




**Carlos S. Duque, MD**, is a head and neck surgeon trained at the University of Miami, Department of Otolaryngology. He works at the Hospital Pablo Tobón Uribe and Clínica las Américas in Medellín, Colombia. Dr. Duque specializes in the treatment and management of thyroid cancer. He has published numerous articles on this topic, as well as a book entitled ¡Uuuyyy, TENGO CANCER DE TIROIDES! Entendiendo la enfermedad y la glandula which is also available in English (Oh no, I HAVE THYROID CANCER!). He has led sessions in both English and Spanish at numerous past ThyCa conferences.



**Rosella Elisei, MD**, is an endocrinologist at University of Pisa in Pisa, Italy. Dr. Elisei is an Associate Professor of Endocrinology at the University of Pisa. She is an expert clinician mainly involved in the management of thyroid cancer patients. Dr. Elisei received numerous international awards: the Light of Life Foundation for the best thyroid cancer researcher of 2011, the 2018 European Thyroid Association award as distinguished scientist in Thyroid research field, the JCEM award for the best clinical paper 2006, 2012, 2015 and 2016. Dr. Elisei is the author of 220 papers published in peer-reviewed Journals, 55 manuscripts in proceedings of meetings and book chapters, as well as more than 300 abstracts for national and international meetings. She also serves as a reviewer for several peer-reviewed journals and holds memberships in several professional associations. She is PI of several clinical trials for new target therapy in advanced thyroid cancer.



**Laura Fugazzola, MD**, is an associate professor of endocrinology and the head of the Center of Excellence in the diagnosis and treatment of thyroid cancer at the Istituto Auxologico Italiano IRCCS, Milan, Italy. Dr. Fugazzola concentrated her clinical and translational studies on differentiated and medullary thyroid cancer, and on thyroid dyshormonogenesis. She is the associate editor of the *European Journal of Endocrinology* and the *Journal of Clinical Endocrinology & Metabolism*. She is also an investigator or principal investigator for phase 3 protocols on TKIs for advanced thyroid cancer. Dr. Fugazzola has been one of the coauthors of the Italian consensus on thyroid cancer published in 2018 and the coordinator of the group which produced the 2019 European Thyroid Association Guidelines on advanced thyroid cancer. She is also the leader of the European Thyroid Association Cancer Group (ETA-CG).



**Sana Ghaznavi, MD**, is an endocrinologist and neuroendocrine tumour team lead at Tom Baker Cancer Centre, Calgary, Alberta, Canada. Dr. Ghaznavi is an academic endocrinologist at the University of Calgary, Canada. She graduated from the University of Alberta medical school, completed internal medicine and endocrinology residency at the University of Calgary, and completed an interdisciplinary thyroid cancer fellowship at Memorial Sloan Kettering Cancer Center in New York, NY. Her practice focuses on the management of thyroid cancer patients. Her research interests include active surveillance of papillary microcarcinomas, re-sensitization therapy for radioiodine refractory thyroid cancer, and personalization of thyroid hormone replacement therapy.



**Ann W. Gramza, MD**, is a medical oncologist and associate professor of medicine at Georgetown University specializing in the treatment of head and neck cancer, thyroid cancer, and other rare endocrine malignancies. Dr. Gramza conducts clinical trials with new targeted therapies and immunotherapy drugs. She has considerable experience in thyroid cancer clinical trials, having been previously employed at NIH where she conducted several thyroid cancer clinical trials with novel therapeutic agents.



**Jo Grey** is the CEO at The Association for Multiple Endocrine Neoplasia Disorders (AMEND), located in Tonbridge, Kent, United Kingdom. Jo ‘fell into’ volunteering for AMEND after being diagnosed with MEN2A in 2000 – the culmination of a dramatic 4-year battle to be diagnosed. Her mother and 2-year-old son were also diagnosed with MEN2A in 2002. Jo has had surgery for two pheochromocytomas, medullary thyroid cancer and has also lost her left shoulder to an MTC metastasis. In 2013 Jo became AMEND’s first salaried CEO, and manages the charity’s projects, and work informing and supporting all those affected with MEN syndromes and associated rare endocrine conditions. Her wish is that more patients with rare endocrine conditions like MEN survive to live with rather than die from their disease.



**Haixia Guan, MD, PhD**, is an endocrinologist and professor of internal medicine at The First Affiliated Hospital of China Medical University in Shenyang, China. She completed her internal medicine residency and her fellowship training in endocrinology at The First Hospital of China Medical University in Shenyang, China, followed by postgraduate training at the Johns Hopkins Hospital and Boston Medical Center. Dr. Guan’s research interests have been management of thyroid disorders, bone metabolic diseases and tumor-related endocrine problems. She has had more than 80 publications. She was actively involved in three important Chinese guidelines for management of thyroid diseases.



**Avital Harari, MD, MSc**, is an endocrine surgeon and associate professor in the Department of Surgery at the UCLA David Geffen School of Medicine, at the University of California Los Angeles in Los Angeles, California. Dr. Harari received her medical degree with distinction at Washington University School of Medicine in St. Louis, graduating in the top 10% of her medical school class. She trained in general surgery at Columbia University in New York City prior to completing her endocrine surgery fellowship at the University of California, San Francisco. Dr. Harari's clinical and research interests include the multidisciplinary management of benign and malignant tumors of the adrenal, thyroid, and parathyroid glands as well as the neuroendocrine pancreas. She is also interested in familial endocrine disorders (such as multiple endocrine neoplasia). She offers a wide range of unique services including retroperitoneal or transabdominal laparoscopic adrenalectomy, mini-incision thyroid and parathyroid surgery, central and modified neck dissection, and laparoscopic removal of pancreatic tumors.



**R. Alex Harbison, MD, MS**, is an assistant professor in the Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins University in Baltimore, Maryland. He completed medical school at the University of Colorado followed by residency and a Master of Science at the University of Washington in Seattle. He completed a Head and Neck Surgical Oncology fellowship at Johns Hopkins and is a Head and Neck Endocrine surgeon scientist studying the mechanisms by which tumor metabolism dysregulates the anti-tumor immune response. Dr. Harbison is funded through a KL2 grant through the Johns Hopkins Institute for Clinical and Translational Research and an American Head and Neck Society / American Academy of Otolaryngology – Head and Neck Surgery Foundation Young Investigator Combined Award.



**Megan R. Haymart, MD**, is an endocrinologist at the University of Michigan in Ann Arbor, Michigan. Dr. Haymart's research focuses on variation in the management of thyroid cancer with an emphasis on the role of patients, providers, and health systems in thyroid cancer diagnosis and treatment. She also studies thyroid cancer outcomes and the rise in thyroid cancer incidence. She is principal investigator of the NCI-funded R01 grant “Treatment Decision Making in Low-Risk Thyroid Cancer” and the AHRQ-funded R01 grant “Imaging Practices and Overdiagnosis of Thyroid Cancer.” Dr. Haymart received her medical degree from Johns Hopkins University School of Medicine, completed internal medicine residency at Johns Hopkins Hospital, and completed a fellowship in endocrinology, diabetes, and metabolism at the University of Wisconsin. She participates in creating the National Comprehensive Cancer Network thyroid carcinoma guidelines.




**Sharon Hickox, MM, LPMT, MT-BC, CCTSI**, is a music therapist at Note-Able Music Therapy Services in Reno, Nevada. Sharon completed a music therapy degree at Saint Mary-of-the-Woods College in 2016. She also has a Master's of Music from Rice University and a Bachelor's of Music from the University of Southern California, both in Percussion Performance. She has completed Neurologic Music Therapy training and is a Certified Clinical Trauma Specialist. She has experience working with children, adolescents, and adults with mental and behavioral health concerns as well as intellectual and physical disabilities. She enjoys providing music therapy for patients in pediatric, oncology, neurology, and extended care units.



**Ana O. Hoff, MD**, is an endocrinologist at the University of Sao Paulo Medical School, Sao Paulo, Brazil. Dr. Hoff graduated from the Universidade De Brasilia (Unb) Faculdade De Medicina. She is an associate physician at the Onco Star Clinic Full Member of D'Or Oncology doctor of the clinical staff of Hospital São Luiz Itaim – Rede D'Or. She is also head of the Endocrinology Service of the Cancer Institute of the State of São Paulo/faculty of medicine at the University of São Paulo. Dr. Hoff completed her residency in endocrinology and metabolism in the combined program of Baylor College of Medicine and University of Texas MD Anderson Cancer Center. She received her doctorate in endocrinology from the Federal University of São Paulo. Dr. Hoff's research focus has included the various types of thyroid cancer, multiple endocrine neoplasia, adrenal carcinoma, osteoporosis, and bone loss in cancer patients.



**Jennifer Holkem** is a thyroid patient advocate, educator, and founder of "Save Your Thyroid," a private Facebook community and future non-profit organization for patients pursuing nonsurgical treatment options for thyroid nodules. In 2019 she was searching for an alternative to surgery for her own thyroid nodules and discovered radiofrequency ablation (RFA). Due to a severe lack of patient-oriented resources on this and other thermal ablation procedures, she created her YouTube channel, "It's me Jen again," where she shares her own experience and creates educational video content on this topic. She is a passionate educator and advocates for patients and doctors to save the thyroid whenever possible.



**Mimi I. Hu, MD**, is an endocrinologist and professor at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Hu has served on the faculty at MD Anderson Cancer Center since 2007. Her clinical expertise is in the evaluation and treatment of patients with papillary, follicular, and medullary thyroid cancers, hereditary endocrine neoplasia disorders, and metabolic bone and mineral disorders. She is the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid cancer. Dr. Hu has published articles and book chapters evaluating the management of medullary thyroid cancer, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders. Dr. Hu is a ThyCa medical advisor.




**Jacqueline Jonklaas, MD, PhD, MPH**, is an endocrinologist at MedStar Georgetown University Medical Center in Washington, D.C. Dr. Jonklaas obtained her MD, residency, and fellowship training at Georgetown University. Dr. Jonklaas is the director of the Georgetown Clinical Research Unit and has published research regarding treatment and outcomes in patients with thyroid cancer. She is the chief operating officer of the American Thyroid Association. She has been a member of the Endocrine Society since 1997 and serves on the editorial board of the *Journal of Clinical Endocrinology and Metabolism* and as a member of the Endocrine Society Self-Assessment Committee.





**Shoko Kure, MD, PhD**, is a post-doctoral research fellow in Dr. Carmelo Nucera's preclinical thyroid cancer research lab at Beth Israel Deaconess Medical Center, Harvard Medical Center, in Boston, Massachusetts. Dr. Kure has a background of diagnostic pathology/ cytology, molecular/experimental pathology. She received her medical degree and PhD (pathology) from Nippon Medical School, Tokyo, Japan. After the residency, she became a junior faculty member in the Department of Pathology at Nippon Medical School and published several peer-reviewed papers. Her subspecialty is thyroid pathology, and her current research interest is in the tumor microenvironment of medullary thyroid cancer. She is a new member of the American Thyroid Association (ATA), declaring that she will dedicate herself to this research, provide new evidence to the ATA, and contribute to the ATA as well as persistent MTC patients with better treatment and diagnostic method. Dr. Kure is a 2022 ThyCa research grant recipient.



**Tom Kurzawinski, MD, PhD FRCS**, is a consultant pancreatic and endocrine surgeon at the University College Hospital, Royal Free Hospital and Great Ormond Street Hospital in London, England. He earned his medical degree and received training in general surgery in Poland. Dr. Kurzawinski continued specialist training and research in liver, pancreas and endocrine surgery in the United Kingdom. He is a fellow of the Royal College of surgeons of Edinburgh and a member of British Association of Thyroid and Endocrine Surgeons, British Society for Endocrinology and Pancreatic Society. He established the Centre for Endocrine Surgery which provides surgical treatments for children and adult patients with diseases of the endocrine glands.




**Jennifer Kwak, MD**, is a nuclear medicine physician at the University of Colorado Hospital in Aurora, Colorado. Dr. Kwak also serves as an Associate Professor of Radiology-Nuclear Medicine and the Nuclear Radiology Fellowship Program Director. She earned undergraduate degree from Dartmouth College, and her medical degree from Tufts University School of Medicine in Boston, MA.



**Theodore W. Laetsch, MD**, is a pediatric oncologist at Children's Hospital of Philadelphia in Philadelphia, Pennsylvania. He leads both the Developmental Therapeutics Program (DVL) and the Very Rare Malignant Tumors Program (VRMTP), as well as holding national leadership roles in each of these areas within the Children's Oncology Group (COG). In the DVL program, Dr. Laetsch conducts early phase clinical trials of new treatments for children with difficult to treat cancers, with a particular area of focus including molecularly targeted therapies that are designed to block specific genetic mutations identified in patients' tumors. Dr. Laetsch leads the pediatric development of TRK inhibitors for children with NTRK gene fusions, and now leads a COG nationwide clinical trial studying the ability to use TRK inhibitors instead of chemotherapy for children with one of these gene fusions.



**Amanda LaGreca, MD**, is an endocrinologist and assistant professor of medicine at the University of Colorado School of Medicine in Aurora, Colorado. She received her medical degree from University of Buenos Aires and completed her residency at Yale-New Haven Medical Center in Connecticut.



**Amanda M. Laird, MD**, is an endocrine surgeon, chief of Endocrine Surgery at Rutgers Cancer Institute of New Jersey as well as an Associate Professor of Surgery at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey. After graduating from Louisiana State University and Louisiana State University Health Sciences Center in Shreveport, Louisiana, she completed her residency in general surgery at Wake Forest University in Winston-Salem, North Carolina. Dr. Laird then completed the Norman Thompson Fellowship in Endocrine Surgery at the University of Michigan. Prior to joining Rutgers Cancer Institute, she was an Assistant Professor of Surgery at Montefiore Medical Center and Albert Einstein College of Medicine where she was Director of Endocrine Surgery. She serves on several committees for both the American Association of Endocrine Surgeons and the Association of Academic Surgery.






**Jessie Larson-Wu, MA, LPC**, Jessie has been a mental health therapist for almost 10 years and is a recent survivor of papillary thyroid cancer. She recently started a podcast called “support through thyroid cancer” to provide support through storytelling and wisdom sharing between folks with a thyroid cancer diagnosis. Her current clinical practice is at a university counseling center providing services to students.



**Michael A. Levine, MD, FAAP, FACP, FACE**, is chief of the Division of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children’s Hospital of Philadelphia. He is a Professor of Pediatrics and Medicine at the University of Pennsylvania Perelman School of Medicine, and he holds the Lester Baker Endowed Chair in Pediatric Diabetes. His primary clinical interests are endocrine diseases that affect bone and mineral metabolism, particularly osteoporosis, primary hyperparathyroidism, hypoparathyroidism, rickets, and genetic bone disease. He has identified the molecular basis of several inherited disorders of mineral metabolism. His research interests extend to the molecular basis for embryological development of the parathyroid glands.



**Jochen H. Lorch, MD, MSc**, is a medical oncologist and professor of medicine and medical director of the Head and Neck and Thyroid Programs Northwestern Medical Group in Chicago, Illinois. He graduated from the University of Regensburg in Germany in 1993 and completed his internship and residency at the University of Pennsylvania/Presbyterian Medical Center in 1999. He was awarded a fellowship in hematology and oncology at Northwestern University in Chicago. In 2002, he returned to Germany to complete his German Board Certification in Internal Medicine and Medical Oncology. He returned to the US in 2005 to take a faculty position at Boston University in Boston, MA and started as a faculty member at Dana Farber Cancer Institute in Boston, MA in 2008. He became the inaugural director of the Thyroid Center at Dana Farber. In 2021 he left Dana Farber as Associate Professor of Medicine to join the faculty at Northwestern University. Dr. Lorch is a ThyCa medical advisor.



**Iftikhar A Malik MD, ECNU, FACE**, is an endocrinologist in Appleton, Wisconsin. Dr. Malik earned his medical degree at Punjab Medical College and completed residency training in pulmonary medicine at DHQ Hospital, both in Pakistan. He received residency training in internal medicine at Kingsbrook Jewish Medical Center in New York and served as the chief medical resident during his studies there. Dr. Malik completed a fellowship program in endocrinology through the Medical College of Wisconsin. He is a great proponent of least invasive techniques and provides Ethanol ablation and Laser ablation for nonmalignant enlarging thyroid nodules.



**Haggi Mazeh, MD, FACS, FISA**, is an endocrine surgeon at Hadassah Medical Center in Jerusalem. He is chairman of the Israel Endocrine Surgery Society and the Chief-of-Surgery at the Department of Surgery, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel. Prof. Mazeh completed his general surgery residency at Hadassah Medical Center and his endocrine surgery fellowship at the University of Wisconsin. He is currently leading a high-volume Endocrine Surgery service and performs numerous thyroid, parathyroid, adrenal, and neuroendocrine surgeries. Prof. Mazeh has multiple and significant scientific contributions in Endocrine Surgery. His research is presented at national and international conferences and is published at high impact factor journals.



**Lizzy McAninch, MD**, is an endocrinologist and clinical associate professor at Stanford Hospital and Clinics in Stanford, California. She received her medical degree from University of Miami Miller School of Medicine. Her research focuses on understanding aspects of thyroid hormone metabolism and genetic differences that impact these pathways.



**David G. McFadden, MD**, is an endocrinologist at UT Southwestern Medical Center in Dallas, Texas. Dr. McFadden is an assistant professor of internal medicine and biochemistry. His clinical interest is in the treatment of tumors arising from endocrine glands, including thyroid cancer. He is a member of the American Thyroid Association and the International Thyroid Oncology Group and has been awarded research grants from the National Institutes of Health, American Thyroid Association, the Disease Oriented Clinical Scholars (DOCS) program at UT Southwestern, and the Cancer Prevention and Research Institute of Texas (CPRIT). His current research focuses on using genetic engineering and chemical screens to discover new treatments for cancer.



**Beverly McLaughlin, MA**, is a patient navigator at the University of Colorado Hospital in Aurora, Colorado. Ms. McLaughlin is a member of the administrative staff in the Division of Endocrinology, Diabetes, and Metabolism.



**Kate Mitchell, MD**, is currently in her final year of medical school at the Albert Einstein College of Medicine and is applying to residency programs. She met Bryn Silverman during her freshman year of college at the world renown USC School of Cinematic Arts where she completed her BA in film and television production alongside Bryn. Prior to attending medical school, Kate wrote, produced, and directed her own films which have been featured in various festivals. She also worked as an assistant to acclaimed directors in the tv/film industry.



**Dr. Lilah Morris-Wiseman, MD, FACS**, is Chief of Endocrine Surgery and Associate Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine in Baltimore, Maryland. She is a high-volume clinical endocrine surgeon who treats diseases of the thyroid, parathyroid, and adrenal glands. Her research interest is in patient symptoms related to thyroid disease and quality of life. She is a national leader in endocrine surgery and surgical education. Among other roles, she serves on the editorial board of *Clinical Thyroidology* and on the American Thyroid Association guidelines committee for Thyroid Disease and Pregnancy.



**David Myssiorek, MD, FACS**, is an otolaryngologist at Bronxcare Health System in Bronx, New York. He is the author of numerous articles on thyroid cancer surgery and other head and neck surgery. A graduate of New York University School of Medicine, Dr. Myssiorek did his internship at Lenox Hill Hospital and was Chief Resident at New York University/Bellevue. He is the author of numerous articles on thyroid cancer surgery and other head and neck surgery. Dr. Myssiorek is a ThyCa medical advisor.



**Caroline Nguyen, MD**, is an endocrinologist and an assistant professor of clinical medicine in the Division of Endocrinology, Diabetes, and Metabolism and the Department of Obstetrics and Gynecology at Keck Medical Center of USC in Los Angeles, California. Her clinical and research interests are related to the diagnosis and treatment of thyroid disease with a special focus on thyroid disorders in pregnancy including hyperthyroidism, hypothyroidism, subclinical thyroid disease, thyroid cancer, Hashimoto's, and postpartum thyroiditis. She has published articles in *Thyroid*, the *Journal of Clinical Endocrinology and Metabolism*, *Clinical Obstetrics and Gynecology*, and *Clinical Diabetes and Endocrinology*.



**Sarah C. Oltmann, MD**, is an endocrine surgeon and the Associate Program Chief of Quality and Best Practice, Medical Director of the General Surgery Clinics, and Director of Endocrine Surgery for Parkland Health and Hospital Systems in Dallas, Texas. She attended Baylor University, graduating cum laude for her undergraduate degree. She went on to earn her medical degree at Texas Tech University Health Sciences Center, graduating Alpha Omega Alpha. She completed her general surgery residency at the University of Texas Southwestern Medical Center. She pursued endocrine surgery fellowship training at the University of Wisconsin in Madison, WI. Her clinical practice focuses on the surgical management of diseases of the thyroid, parathyroid and adrenal glands. Research interests include management and clinical outcomes in endocrine surgery. She is a previous recipient of the ATA/ThyCa Research Grant for her work on cancer progression and therapeutic response in a mouse model of Medullary Thyroid Cancer. She is happily married, with two sons. She is an avid knitter.



**Theodora Pappa, MD, PhD**, is an onco-endocrinologist and physician scientist committed to precision medicine in thyroid cancer. Her clinical practice at Brigham and Women's Hospital/Dana-Farber Cancer Institute is thyroid focused and she conducts translational research on thyroid cancer genomics collaborating with colleagues from Harvard Medical School and the Broad Institute. The focus of her research activities is to chart the tumor ecosystem in thyroid cancer and leverage the advances of next generation sequencing and novel computational approaches in order to dissect and clinically interpret thyroid cancer genome, and eventually develop novel prognostic biomarkers to help advance thyroid cancer care. Dr. Pappa is a 2022 ThyCa research grant recipient.



**Kepal N. Patel, MD**, is the Chief of the Division of Endocrine Surgery and a Professor of Surgery, Otolaryngology and Biochemistry at NYU Langone Health in New York. He is the Director of the Thyroid Interdisciplinary Program and has particular expertise in the multidisciplinary treatment of Thyroid and Parathyroid disease along with other head and neck tumors. He is also the Director of Mentoring and Faculty Development in the Department of Surgery. Dr. Patel has been studying the molecular pathogenesis of thyroid carcinoma by focusing on the changes in intracellular pathways that lead to the progression of thyroid cancer.



**Susan Pitt, MD, MPHS**, is an associate professor of surgery and director of Endocrine Surgery Health Services Research at the University of Michigan in Ann Arbor, MI. Dr. Pitt's clinical practice focuses on surgical treatment of thyroid, parathyroid, and adrenal gland disease. Dr. Pitt's research is funded by the National Cancer Institute and focuses on improving patient outcomes, patient-doctor communication, and treatment decision making, while reducing unnecessary care for patients with thyroid cancer. To facilitate this work, Dr. Pitt founded the CHOICE Collaborative to Compare Health Outcomes in Cancer Experience. Dr. Pitt received her medical degree from the Medical College of Wisconsin and her Master's in Population Health Science from Washington University in St. Louis. She completed her general surgery residency at Washington University in St. Louis and an Endocrine Surgery fellowship at Brigham and Women's Hospital in Boston, MA.



**Eyal Robenshtok, MD**, is an endocrinologist at Beilinson Hospital and Davidoff Cancer Center in Petah Tikva, Israel. He graduated from the Hadassah Medical School in Jerusalem with his MD degree and completed his training in internal medicine and endocrinology at the Rabin Medical Center. In 2012 he completed the thyroid cancer fellowship at Memorial Sloan-Kettering Cancer Center, New York. Dr. Robenshtok believes in compassionate, state of the art medical treatment, with shared decision making to achieve the best goals for each individual patient. His research focuses on individualized, risk stratified management of thyroid cancer, and his studies were published in leading scientific journals, including JCEM, Thyroid and more. He is an active member of these professional organizations: ATA, ETA, IES, EORTC and ITOG.





**Bruce Robinson, MD**, is an endocrinologist and professor at the University of Sydney, Sydney, Australia. He has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital, since 1989. He has been chairman Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam since 2001. In 2015 Dr. Robinson was appointed as chair of Australia's peak advisory and funding body for medical research, National Health and Medical Research Council. His research has focused on identifying genetic changes which either predispose or directly cause endocrine tumors, and among other highlights has been the formation of an international consortium of families from around the world to study medullary thyroid carcinoma and pheochromocytoma.



**Mabel Ryder, MD**, is an endocrinologist at the Mayo Clinic in Rochester, Minnesota. She earned her medical degree from the University of Texas and completed her fellowship and residency at the University of Cincinnati College of Medicine. Dr. Ryder specializes in head and neck cancer and nuclear medicine therapy. She has contributed to many publications on thyroid cancer. Dr. Ryder is a 2007 ThyCa research grant recipient.



**Anna Sawka, MD, PhD**, is a clinician scientist and endocrinologist at Toronto General Hospital Research Institute in Toronto, Canada. Dr. Sawka was recently promoted to professor in the Division of Endocrinology, Department of Medicine at the University of Toronto. She holds a PhD in Health Research Methodology/Biostatistics and Epidemiology from McMaster University. Her research focus is primarily in thyroid cancer.




**Donna Sherman, MSW, LCSW**, is a clinical social worker and thyroid cancer survivor based out of Highland, New York and New York City. Since 2008 she has been working as a behavioral health coach and consultant offering skills-based guidance and training that helps clients live and work well. In 2016 she created the therapeutic guided restorative recording titled: Yoga Nidra: Total Relaxation Practices for Adults & Teens. Ms. Sherman currently hosts the Sparks In Action Podcast.



**Donald L. Siegel, MD, PhD**, is Professor of Pathology & Laboratory Medicine and Director of Transfusion Medicine & Therapeutic Pathology at the University of Pennsylvania. He is medical director of the blood bank, apheresis unit, and stem cell laboratory, and director of Penn's Center for Advanced Cellular Therapies which developed and administered to patients the first successful chimeric antigen receptor T cells (CAR-T) therapies for leukemia and first-in-human use of CRISPR-edited cells. Dr. Siegel received an undergraduate degree in biophysics from Brown University, a Ph.D. in biophysics from Harvard University, and an M.D. from the University of Pennsylvania School of Medicine. After clinical pathology residency and fellowship training in blood banking/transfusion medicine, he joined the faculty at UPenn. Dr. Siegel's translational research laboratory focuses on the discovery of recombinant antibodies relevant to benign hematology, infectious diseases, and oncology, particularly for the design of novel CAR-T therapies.



**Bryn Silverman** is a filmmaker and graduate of the University of Southern California School of Cinematic Arts. She is an Associate Programmer for the Tribeca Film Festival. Her work examines myth making in American history. She was a story producer for Netflix's documentary series Amend: The Fight for America and an editor of the critically acclaimed documentary film Roll Red Roll. She is currently producing a film that follows her experience with papillary thyroid cancer.



**Laura Slagle, MA, LMFT**, is the founder, CEO and Clinical Director of Olive Leaf Family Therapy, Inc. in Fresno, CA. Laura has a staff of 12 therapists, some of them with specialties in working with individuals with chronic health problems and/or disabilities. With over three decades of experience working with adults, couples, children and families as an educator, administrator, advocate, case manager, and mental health professional, Laura connects with her patients from a place of understanding and compassion and believes that “love really is enough”, not to cure all hardships but to endure all we come across in our life journeys. Laura’s ultimate goal is to reach her community and beyond with a message of hope, love, healing, and healthy relationships. Laura is also a thyroid cancer survivor. After her diagnosis and thyroidectomy in Fall 2011, she underwent radioactive iodine treatment in Winter 2012. Thankfully, she has had no recurrence since then.



**Grant M. Smith, MD**, is a clinical assistant professor of medicine at the Stanford School of Medicine, where he works on the inpatient palliative care consult service and in the outpatient palliative care clinic. He is the medical director of the Stanford Palliative Care Community Partnerships Team, which raises awareness and understanding of palliative care in the community. He received his medical degree from Harvard Medical School and completed internal medicine residency and palliative care fellowship at the University of California, San Francisco.



**Julie Ann Sosa, MD, MA, FACS, FSSO**, is an endocrine and oncologic surgeon at the University of California, San Francisco in San Francisco, California. She is also Chair, Department of Surgery and Professor in the Departments of Surgery and Medicine. Her previous position was at Duke University Medical Center in Durham, North Carolina. She is a principal investigator or co-principal investigator of studies of new drug treatments for differentiated thyroid cancer (papillary/follicular), medullary thyroid cancer, and anaplastic thyroid cancer. Following undergraduate education at Princeton University, she received an MA in Human Sciences at the University of Oxford in the United Kingdom and her medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She received postgraduate training at Johns Hopkins Hospital as well as John Radcliffe and Churchill Hospitals in Oxford, England. Dr. Sosa is a ThyCa medical advisor.



**Susan Spinosa** is the founder and president of NTRKers.org. Susan is a thyroid cancer survivor since 2004. In 2018, Susan was diagnosed with NTRK gene fusion positive thyroid cancer. Her main focus has been education and connecting patients, family, and care partners for those affected by any NTRK positive cancer. She feels it is also important to advance medical community education and the importance of biomarker tumor testing. In addition, Susan is a volunteer with the ThyCa: Thyroid Cancer Survivors' Association, Inc., Cancer Hope Network and the Biomarker Collaborative.



**Christine Spitzweg, MD**, is an endocrinologist at Medizinische Klinik und Poliklinik IV in Munich, Germany. Dr. Spitzweg is a professor of medicine at the Department of Internal Medicine II, Ludwigs-Maximilians-University (LMU) Munich Campus Grosshadern. She obtained her medical degree from the Munich Medical School, LMU Munich. Dr. Spitzweg is the chair of the thyroid center and the co-chair of the center for neuroendocrine tumors at the LMU Munich. Dr. Spitzweg has been involved in both clinical practice and research with a special interest in benign and malignant thyroid disease. She directs the research laboratory for Molecular Endocrinology investigating expression and regulation of the sodium iodide symporter (NIS) in and outside of the thyroid gland, the role of NIS as a novel reporter and therapy gene in the management of non-thyroidal and thyroidal cancer as well as regulation of mesenchymal stem cell tumor homing and differentiation by thyroid hormones.



**Cord Sturgeon, MD, MS**, is the chief of endocrine surgery at Northwestern University Feinberg School of Medicine in Chicago, Illinois. He also serves as a physician Director of Informatics for the NMHC system since 2015. He completed his residency at the University of Illinois Hospital, and his fellowship at the University of California San Francisco Medical Center. His academic focus was clinical outcomes for thyroid cancer, hyperparathyroidism, and adrenal tumors including pheochromocytoma and adrenal cancers. Dr. Sturgeon's clinical focus is the treatment of thyroid and parathyroid disease. He has a special interest in Multiple Endocrine Neoplasia.



**Vivek Subbiah, MD**, is a clinical trialist and physician investigator at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is an associate professor in the Investigational Cancer Therapeutics department. He is the Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine division. Dr. Subbiah has a unique training background as he is one of the few physicians in the nation/world to have training in oncology in both adults and children. He is board certified in both Internal Medicine and Pediatrics and has completed fellowships in both adult and pediatric oncology at MD Anderson. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a specialist interest in anti-body drug conjugates, radio-pharmaceuticals, immunoconjugates and basket trials.



**Vineeth K. Sukrithan, MD**, is a medical oncologist and assistant professor in the Division of Medical Oncology at Ohio State University Comprehensive Cancer Center in Columbus, Ohio. Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer.



**Valentina D. Tarasova, MD**, is an endocrinologist at Moffitt Cancer Center in Tampa, Florida. Dr. Tarasova received her MD at Kubansky State Medical University. She completed an internal medicine residency at Yale New Haven Hospital, Yale School of Medicine, New Haven, CT and an endocrinology, diabetes and metabolism fellowship at the University of Omaha, NE. Most recently, Dr. Tarasova has completed a thyroid cancer fellowship at Memorial Sloan Kettering Cancer Center. Dr. Tarasova's clinical interests include thyroid neoplasm, particularly diagnosis, monitoring and treatment of thyroid carcinoma (from low risk to advanced progressive forms of thyroid cancer). Her research interests include the role of molecular markers in diagnosing and determining the prognosis of thyroid neoplasm, risk stratification of patients with thyroid cancer and developing tools to estimate the prognosis and determine the management of patients with thyroid cancer.



**Ralph P. Tufano, MD**, is an otolaryngologist at Sarasota Memorial Health Care System in Sarasota, Florida. Dr. Tufano is the Medical Director of Head and Neck Endocrine Surgery at Sarasota Memorial's First Physicians Group Thyroid and Parathyroid Center. Dr. Tufano specializes in thyroid and parathyroid surgery including the management of hyperparathyroidism, thyroid nodules, early, advanced and recurrent thyroid cancer, neck lymph node metastases, goiter and Graves' disease. His expertise and novel treatment techniques have helped personalize treatment and improve surgical outcomes for patients with these conditions. From 2009-2015, he directed the Johns Hopkins Hospital Multidisciplinary Thyroid Tumor Center.





**R. Michael Tuttle, MD**, is an endocrinologist at Memorial Sloan-Kettering Cancer Center in New York, New York. Dr. Tuttle is also a professor of medicine at the Joan and Sanford I. Weill Medical College of Cornell University. Dr. Tuttle's research projects in radiation-induced thyroid cancer have taken him from Kwajalein Atoll in the Marshall Islands to the Hanford Nuclear power-plant in Washington State to regions in Russia that were exposed to fallout from the Chernobyl accident. He served on the American Thyroid Association committee that produced the current guidelines for the management of benign and malignant thyroid nodules. He also chaired the National Comprehensive Cancer Network Thyroid Cancer panel and served on the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food and Drug Administration. Dr. Tuttle is a ThyCa medical advisor.



**Danica Vodopivec, MD**, is an oncologic endocrinologist and assistant professor of medicine at The University of Alabama at Birmingham, Department of Endocrinology, Diabetes and Metabolism in Birmingham, Alabama. After obtaining her medical degree at Universidad de Guayaquil in Ecuador, she completed an Internal Medicine residency at Lahey Clinic/Tufts University in Burlington, MA. She did her Endocrinology fellowship at Boston Medical Center/Boston University School of Medicine in Boston, MA followed by an oncologic endocrinology specialty fellowship at The University of Texas MD Anderson Cancer Center, Houston, TX. Throughout her training years she has participated in clinical and bench research dedicated to parathyroid neoplasia, multiple endocrine neoplasia syndrome, and tyrosine kinase inhibitors resistance mechanisms in thyroid cancer. Her scholarly activities have resulted into several peer-reviewed articles, book chapters, and quality improvement projects dedicated to better serve the community of patients presenting with various types of endocrine neoplasia, in particular advanced thyroid cancer.



**Jonathan Wadsley, MA, MRCP, FRCR**, is an oncologist at Weston Park Hospital, in Sheffield, United Kingdom. He also serves as professor, Department of Oncology and Metabolism, University of Sheffield. His clinical interests are in thyroid cancer, neuroendocrine tumours and pancreatic/biliary tract cancers. He is a member of the Sheffield European Neuroendocrine Tumour Society Centre of Excellence team and provides clinical leadership for the Sheffield molecular radiotherapy service. Dr. Wadsley is the academic director for the directorate of Specialised Cancer Services and Clinical Director of the Sheffield Cancer Clinical Trials Centre. He has numerous national roles, including NIHR National Specialty Lead for Radiotherapy and Imaging, NIHR Cluster co-lead, chair of the NCRI Thyroid Cancer Group, and a member of ARSAC.



**Zhuoying Wang MD, PhD**, is an endocrinologist and professor and chief of the Department of Head and Neck Surgery, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, in Shanghai, China. Dr. Wang graduated from Fudan University Shanghai Medical School in 2000. He completed his surgical oncology residency and fellowship training in Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center in Shanghai, China. He completed research training at the University of Texas M.D. Anderson Cancer Center in Houston. He is member of American Head and Neck Society (AHNS) and American Association of Clinical Endocrinologists (AACE). He serves as President-elected of Thyroid cancer Committee in Chinese Society of Clinical Oncology (CSCO). He has been actively involved in several Chinese guidelines for management of thyroid diseases.



**Jonathan Wasserman, MD, PhD**, is a pediatric endocrinologist and associate professor at The Hospital for Sick Children, Toronto, Ontario, Canada. He also serves as a project investigator of genetics and genome biology at the Research Institute. Dr. Wasserman's research focuses primarily on pediatric thyroid cancer and spans both clinical and translational domains. His research includes genetics and genomics of pediatric papillary thyroid cancer, health care utilization patterns among young patients with thyroid cancer at diagnosis and during follow-up and the identification of prediction models to improve assessment of thyroid nodules in children and to gauge malignant potential. He received his medical training at Harvard Medical School and the Massachusetts Institute of Technology and subsequently pursued an internship and residency in pediatrics at Children's Hospital in Boston. He previously earned a PhD and completed postdoctoral training in genetics at the University of Cambridge, England. Dr. Wasserman serves as co-chair of the American Thyroid Association's (ATA) Pediatric Thyroid Cancer Guidelines.



**Linwah Yip, MD**, is an associate professor of surgery in the Division of Breast/Endocrine Surgery and Surgical Oncology, and holds a secondary appointment with the Clinical and Translational Science Institute at the University of Pittsburgh. Her research and clinical interest are the utility of molecular markers to guide management of indeterminate thyroid nodules and to direct extent of surgery for thyroid cancer. She is the program director for Complex General Surgical Oncology Fellowship and is the Co-Chief of the Division of Endocrine Surgery.



**Mark E. Zafereo, MD**, is a head and neck surgeon and associate professor at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is section chief of head and neck endocrine surgery and associate medical director of the Endocrine Center. He holds national committee appointments for professional associations and is past president of the Houston Society of Otolaryngology-Head and Neck Surgery. His clinical practice focuses on patients with thyroid cancer and parathyroid neoplasms. Dr. Zafereo is a ThyCa medical advisor.

